Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying a new drug, uproleselan, to see if it is safe and effective
in decreasing relapse after stem cell transplant and improving leukemia-free survival in
pediatric patients with acute myeloid leukemia (AML).
The name of the study drugs involved in this study are:
- Uproleselan
- Busulfan
- Clofarabine
- Fludarabine
- Tacrolimus
- Methotrexate
- Mycophenolate Mofetil